대한Helicobacter 연구학회지 Search

CLOSE


대한Helicobacter 연구학회지 2002;2(2):241-245.
Published online November 21, 2002.
Recent Updates in Helicobacter pylori Vaccination
헬리코박터 파일로리 백신의 최신 지견
김경모
울산대학교 의과대학 서울아산병원 소아과
Abstract
Recent progress in the development of a vaccine against Helicobater pylori(H. pylori) will be discussed in this review. To date, this Gram-negative, spiral shaped bacterium is the most common infections of the human. H. pylori infection has known to be associated with chronic gastritis, peptic ulcer diseases and gastric cancer. Antimicrobial therapy is currently the method of choice for curing H. pylori infection, but complex dosing, inconsistent efficiency, development of antibiotic resistance, costs and various side effects compromise widespread use. As a consequence, vaccines are an attractive option, because they are both effective and economic in use. Natural infection with H. pylori usually results in a strong inflammatory Th1-type CD4(+⁢) T-cell response that does not seem to have any protective effects. Successful vaccination studies indicate that a Th2-type response is required for protection, but the exact mechanisms involved in protective immunization are still poorly understood. Although commercial development of products for clinical trial is underway, many important issues, such as lack of a suitable mucosal adjuvant, and prevention of potential side effects, such as postimmunization gastritis, need to be resolved. (Korean J Helicobacter Res Prac 2002;2:241-244)
Key Words: Helicobacer pylori, Vaccine


Editorial Office
Lotte Gold Rose II Room 917, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-717-5543    Fax: +82-2-565-9947    E-mail: helicojournal@smileml.com                

Copyright © 2024 by Korean College of Helicobacter and Upper Gastrointestinal Research.

Developed in M2PI

Close layer
prev next